secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001193125-25-279072
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel Q3 net loss $11.3M; cash $87M; secures $130M debt facility with Trinity Capital
--------------------------------------------------------------------------------

- Net loss of $11.3M vs $10.6M in Q3 2024; R&D expenses $8.5M, G&A $4.7M.
- Cash and equivalents $87.0M as of Sept 30, 2025; plus $50M upfront from Trinity Capital facility to fund operations into Q1 2027.
- Entered $130M term loan with Trinity Capital Inc.; $50M drawn at closing, up to $80M additional subject to milestones.
- BLA submission for CAN-2409 in localized prostate cancer planned Q4 2026; phase 3 NSCLC trial to start Q2 2026.
- Pausing pancreatic cancer program (PDAC) unless external non-dilutive funding obtained.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000119312525279072/0001193125-25-279072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000119312525279072/cadl-20251113.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-279072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer